best practice onkologie

, Volume 7, Issue 1, pp 4–11

Molekularpathologische Grundlagen für die Therapie des NSCLC

Die „stille Revolution“ in der Behandlung solider Tumoren
TOPIC 1 molekularpathologische grundlagen beim nsclc

In der Behandlung solider Tumoren findet seit ca. 5 Jahren eine rasante Entwicklung, ja fast eine „stille Revolution“ statt. Insbesondere bei Entitäten, die mit geringer Überlebensperspektive verbunden waren (und z. T. noch sind), bestehen zumindest für einige Subgruppen signifikant verbesserte Möglichkeiten. Um diese Patientengruppen zu identifizieren, müssen die entsprechenden genetischen Veränderungen erkannt werden.

Literatur

  1. [1]
    Cappuzzo F et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521–529PubMedCrossRefGoogle Scholar
  2. [2]
    Flaherty KT et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med363: 809–819PubMedCrossRefGoogle Scholar
  3. [3]
    Gatzemeier U et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25: 1545–1552PubMedCrossRefGoogle Scholar
  4. [4]
    Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359: 1367–1380PubMedCrossRefGoogle Scholar
  5. [5]
    Hirsch FR et al (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21: 3798–3807PubMedCrossRefGoogle Scholar
  6. [6]
    Horn L, Pao W (2009) EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27: 4232–4235PubMedCrossRefGoogle Scholar
  7. [7]
    Janku F et al (2011) PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6: e22769CrossRefGoogle Scholar
  8. [8]
    Jemal A et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100: 1672–1694PubMedCrossRefGoogle Scholar
  9. [9]
    Jin, G et al (2010) PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 69: 279–283PubMedCrossRefGoogle Scholar
  10. [10]
    Ladanyi M, Pao W (2008) Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21 (Suppl 2): 16–22CrossRefGoogle Scholar
  11. [11]
    Li J et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947PubMedCrossRefGoogle Scholar
  12. [12]
    Marchetti A et al (2007) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23: 857–865CrossRefGoogle Scholar
  13. [13]
    Mascaux C et al (2005) The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92: 131–139PubMedCrossRefGoogle Scholar
  14. [14]
    Meert AP et al (2002) The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 20: 975–981PubMedCrossRefGoogle Scholar
  15. [15]
    Mok TS et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957PubMedCrossRefGoogle Scholar
  16. [16]
    Murray S et al (2008) Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 3: 832–839PubMedCrossRefGoogle Scholar
  17. [17]
    Nguyen KS, Kobayashi S, Costa DB (2009) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10: 281–289PubMedCrossRefGoogle Scholar
  18. [18]
    Paik PK et al (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29: 2046–2051PubMedCrossRefGoogle Scholar
  19. [19]
    Parra HS et al (2004) Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‚Iressa', ZD1839) in non-small-cell lung cancer. J Cancer 91: 208–212Google Scholar
  20. [20]
    Pirker R et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525–1531PubMedCrossRefGoogle Scholar
  21. [21]
    Riely GJ, Marks J, Pao W (2009) KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6: 201–205PubMedCrossRefGoogle Scholar
  22. [22]
    Rosel R et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958–967CrossRefGoogle Scholar
  23. [23]
    Schiller JH et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92–98PubMedCrossRefGoogle Scholar
  24. [24]
    Sharma SV, Bel DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169–181PubMedCrossRefGoogle Scholar
  25. [25]
    Sullivan KM, Kozuch PS (2011) Impact of KRAS mutations on management of colorectal carcinoma. Patholog Res Int 219309Google Scholar
  26. [26]
    Takano T et al (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 6829–6837PubMedCrossRefGoogle Scholar
  27. [27]
    Tsao MS et al (2005) Erlotinib in lung cancer — molecular and clinical predictors of outcome. N Engl J Med 353: 133–144PubMedCrossRefGoogle Scholar
  28. [28]
    Yamamoto H et al (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68: 6913–6921PubMedCrossRefGoogle Scholar
  29. [29]
    Zhang X, Chang A (2008) Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci 5: 209–217PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.HämatopathologieHamburgDeutschland
  2. 2.Hämatopathologie HamburgHamburgDeutschland

Personalised recommendations